Mark Voskoboynik

机构：Alfred Health, Monash University · ORCID：0000-0002-4242-1300

发表论文 137 篇 · 总被引 1582 次 · h-index 19

代表论文

• Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity (2025 · Investigational New Drugs · 被引 8)
• Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer (2025 · JAMA Oncology · 被引 5)
• A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results (2025 · Cancer Chemotherapy and Pharmacology · 被引 4)
• First-in-human study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced cancer. (2025 · Journal of Clinical Oncology · 被引 2)
• 595 Preliminary results of safety and antitumor activity from a first-in-human phase 1 study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced tumors (2025 · Regular and Young Investigator Award Abstracts · 被引 1)
• 923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors (2025 · Annals of Oncology · 被引 1)